Scientists have identified which variations of a specific gene determine a patient’s initial response to treatment with the blood-thinning (anticoagulant) drug warfarin. Researchers found that the gene VKORC1 plays a major role in determining a patient’s initial sensitivity to warfarin treatment — when dosage amounts are most critical to prevent clotting problems in patients.